Posters
« Back
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
EP22213
Poster Title: Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Submitted on 02 Sep 2014
Author(s): Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)
Affiliations: (1) Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden
This poster was presented at ELRIG Drug Discovery 2014
Poster Views: 2,380
View poster »


Poster Information
Abstract: Back-scattering interferometry (BSI) is an emerging label-free, conformation-sensitive detection technology for quantitative mass- and matrix-independent biophysical characterization of small molecule interaction with complex drug target proteins under native-like conditions (1). Integral membrane proteins such as GPCRs are critical targets for drug discovery but present a host of challenges to the investigation of their biophysical properties. Of paramount interest to drug discovery efforts is the characterization of the interaction of GPCRs with small molecule compounds as a component of library screening, mechanism of action (MOA) determination, drug candidate profiling, and other aspects of intermolecular binding that inform pharmacology and medicinal chemistry. The difficulty associated with obtaining small molecule affinity data for functionally intact GPCRs effectively restricts the range of assay techniques suited to quantifying these interactions in vitro.

Herein, we describe the application of BSI to the characterization of small molecule ligand binding to human GPR39 overexpressed in crude membrane fractions in free solution. GPR39 is a Zn2+-responsive GPCR under investigation as a therapeutic target for type-2 diabetes (2). The ability to measure the affinity of small molecule agonists such as Zn2+is especially novel, given the unfavorable mass ratio and fast off rate that complicates the use of more established binding assays. Results from screening representatives from multiple novel GPR39 agonist series is presented, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.
Summary: We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffoldsReferences: 1. Bornhop DJ, Latham JC, Kussrow A, Markov DA, Jones RD, Sorensen HS. Free-solution, label-free molecular interactions studied by back-scattering interferometry. Science. 2007 Sep 21;317(5845):1732-6.

2. Popovics P, Stewart AJ. GPR39: A zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci. 2011 Jan;68(1):85-95.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Streamlining Biologics Development with the Expi Expression Systems
Chao Yan Liu, Jian Liu, Wanhua Yan, Kyle Williston, Kenneth Thompson, Maya Yovcheva, Sara Barnes, Mark Bundy, Melissa Cross, Katy Irvin, Joaquín Canay, Mary Reynolds, Natasha Lucki, Henry Chiou, Andrew Campbell, Jonathan Zmuda

ExpiSf™ Expression system: A Chemically Defined Baculovirus-Based System for Enhanced Protein and Virus Production in Sf9 Cells
Kenneth Thompson, Maya Yovcheva, Sara Barnes, Melissa Cross, Katy Irvin, Natasha Lucki, Henry Chiou, and Jonathan Zmuda

Optimized Expression of Membrane Proteins in the Expi293 and ExpiCHO Expression Systems: New Tools for Difficult to Express Proteins
Chao Yan Liu1, Jian Liu1, Wanhua Yan1, Sam Stepnowski1 ,Kyle Williston1, Katy Irvin1, Chetana Revankar2, Natasha Lucki2, Henry Chiou2, Jonathan Zmuda1. Thermo Fisher Scientific, 1Frederick, MD, U.S.A, 2Carlsbad, CA, U.S.A

Primary Human Hepatocytes 3D in vitro Culture Model for Studying Hepatic Function
Sujoy Lahiri, Julia Tritapoe, Kate Comstock, Michael F. Millett, Mark Kennedy, Theresa V. Nguyen, Deborah K. Tieberg, David T. Kuninger

Donkey Milk Based Products: An innovative Cottage Enterprise for Enhancing Farmers Income
Anuradha Bhardwaj, Yash Pal, Varij Nayan, R.A. Legha, Hema Tripathi, B.N. Tripathi